# What Tripling the Dose Buys

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/what-tripling-the-dose-buys

> A higher semaglutide dose produced 18.7% weight loss against 15.6% on the standard dose. Three extra percentage points is the benefit; the costs are in the safety table.

## Key points

- −18.7% at 7.2 mg vs −15.6% at 2.4 mg over 72 weeks, a gap of 3.1 percentage points.
- Dysaesthesia in 22.9% at 7.2 mg vs 6.0% at 2.4 mg and 0.5% on placebo. Nearly one in four.
- GI events 70.8% vs 61.2%.
- Serious adverse events were LOWER at the higher dose. In a 201-person arm, that is almost certainly noise.
- Active-controlled: it answers 'better than what you'd otherwise get', not 'better than nothing'.
- Novo Nordisk funded.

A higher dose of semaglutide, 7.2 mg, was tested head to head against the standard 2.4 mg[2] in 1,407 people over 72 weeks. It produced **18.7% weight loss against 15.6%**.[1] Three extra percentage points is the benefit. The costs are in the safety table, and one of them is a side effect that is far less common at the standard dose.

## What the trial did

Adults with a BMI of 30 or above and without diabetes were randomized five-to-one-to-one across 95 centers in 11 countries: 1,005 to semaglutide 7.2 mg, 201 to 2.4 mg, and 201 to placebo, for 72 weeks. Participants averaged 47 years old, 113 kg, and a BMI of 39.9, and 73.7% were women.

The lopsided allocation is deliberate. The question is what the new dose does, so most participants go there; the comparison arms only need to be large enough to anchor it.

*STEP UP at 72 weeks. The 2.4 mg column is the one that matters for this decision.[1]*

|   | 7.2 mg | 2.4 mg | Placebo |
| --- | --- | --- | --- |
| Weight change | **−18.7%** | **−15.6%** | −3.9% |
| Gastrointestinal events | 70.8% | 61.2% | 42.8% |
| **Dysaesthesia** | **22.9%** | **6.0%** | 0.5% |
| Serious adverse events | 6.8% | 10.9% | 5.5% |

Against the standard dose, the higher one gave an estimated 3.1 percentage points more weight loss (95% CI −4.7 to −1.6) and 2.4 times the odds of reaching a 25% reduction (95% CI 1.6 to 3.5). Waist circumference fell 11.7 cm more than placebo.

## The side effect that is new at this dose

> **Dysaesthesia (abnormal, often unpleasant sensation, typically tingling or altered touch) occurred in 22.9% of the 7.2 mg group, against 6.0% at 2.4 mg and 0.5% on placebo.** That is nearly one in four. It is the only finding in this table that is not an ordinary feature of the drug class, and it scales steeply with dose.

Gastrointestinal effects also rose (70.8% against 61.2%), but those are familiar, expected, and mostly fade. An unfamiliar sensory effect appearing in a quarter of people at a higher dose is a different kind of information, and it deserves to be named rather than folded into a total.

> Three more percentage points of weight loss, and seventeen more of altered sensation.

The trial’s own interpretation is that the higher dose retained a favorable risk-benefit profile. That may well be right for someone who has not reached their goal at 2.4 mg and for whom the extra loss matters. It is a judgment rather than a measurement, and a reader given both columns can make their own.

## The row that goes the other way

Serious adverse events were *lower* at 7.2 mg (6.8% against 10.9% at 2.4 mg). Reported alone, that reads as the higher dose being safer, which is almost certainly wrong.

The 2.4 mg arm contained 201 people against 1,005 at the higher dose. In a group that size, a handful of unrelated events shifts the percentage by whole points, and 10.9% versus 6.8% is within what chance produces. We include the row anyway. Leaving out inconvenient numbers is the practice this register documents in sellers, and the rule applies to results that favor a drug as much as to ones that do not.

## Reading the 2.4 mg column

> **The standard dose achieved −15.6% here, against the −14.9% everyone remembers from STEP 1.** Those are different trials with different participants and different placebo arms, and setting them side by side is a comparison we decline to make. What the 15.6% *is* good for is the comparison the trial was designed for: against 7.2 mg, in the same people, at the same time.

That is the value of an active-controlled design. Most trials answer “is this better than nothing.” This one answers “is this better than what you would otherwise be prescribed,” which is the question a patient faces.

Two closing notes. The trial was funded by Novo Nordisk, which makes semaglutide. And for what the higher dose costs in dollars rather than side effects, see [what 7.2 mg costs](https://glpwatchdog.org/research/wegovy-7-2-mg-what-it-costs).

STEP UP tested the approved product,[2] and its result does not transfer to compounded semaglutide. If that is what you buy, the seller sets both the dose range and how price follows dose. [KERNX Health](https://glpwatchdog.org/reviews/kernx-health) charges one monthly price across semaglutide doses from 0.22 to 2.5 mg weekly. [Recovery Delivered](https://glpwatchdog.org/reviews/recovery-delivered) charges more as the dose climbs, and [Luma Health Co](https://glpwatchdog.org/reviews/luma-health) publishes a price for every dose, so the cost of each step is visible in advance. At [You4You](https://glpwatchdog.org/reviews/you4you) a month of compounded semaglutide is $180 to $200 at 0.25 mg and $280 to $300 at 2.5 mg, its top dose. [Doko MD](https://glpwatchdog.org/reviews/doko-md) also prices each four-week supply by dose, but its steps are small: $94 at 0.25 mg a week and $116 at 2.4 mg, with shipping extra.

Some sellers carry both sides of that line. [Effecty](https://glpwatchdog.org/reviews/effecty) charges one price at every dose of its compounded semaglutide and also lists brand Wegovy and Ozempic, so a move from the compounded drug to the approved product that STEP UP studied would not mean starting over with a new seller. [Found](https://glpwatchdog.org/reviews/found) also charges one price at every dose of its compounded semaglutide and prescribes the brand-name pens and pills, Foundayo included.

[PrescribedRX](https://glpwatchdog.org/reviews/prescribedrx), [Whoosh Wellness](https://glpwatchdog.org/reviews/whoosh-wellness) and [Nirwana Health](https://glpwatchdog.org/reviews/nirwana-health) charge the same at every dose, and [Basal Health](https://glpwatchdog.org/reviews/basal-health) does the same for the one drug it sells, compounded tirzepatide. [The Aesthetic Concierge](https://glpwatchdog.org/reviews/the-aesthetic-concierge) bills in five-week blocks, which changes the arithmetic of any monthly comparison. None of that is a reason to move up a dose; that call belongs to your prescriber.

## Frequently asked questions

### How much more weight does semaglutide 7.2 mg produce?

In STEP UP, 18.7% against 15.6% on the standard 2.4 mg dose over 72 weeks. That is an estimated 3.1 percentage points more, with 2.4 times the odds of reaching a 25% reduction.

### What is the trade-off?

Gastrointestinal events rose from 61.2% to 70.8%, and dysaesthesia (abnormal or unpleasant sensation, usually tingling) rose from 6.0% to 22.9%. That second one affects nearly one in four people at the higher dose.

### What is dysaesthesia?

Altered or unpleasant sensation, typically tingling or changed sensitivity to touch. It occurred in 0.5% of the placebo group, so it is dose-related rather than a background complaint.

### Were serious adverse events higher at the higher dose?

They were lower (6.8% against 10.9%), but the standard-dose arm held only 201 people against 1,005, so that difference is within what chance produces in a group that size.

### Is the higher dose worth it?

That depends on how much the extra three percentage points matter to you and how you weigh a one-in-four chance of altered sensation. The trial calls the balance favorable, which is a judgment rather than a measurement.

## References

1. Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology. 2025. PMID: 40961952. https://pubmed.ncbi.nlm.nih.gov/40961952/
2. Novo Nordisk WEGOVY (semaglutide) injection and tablets — prescribing information (sections 2.2, 3). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

---

Cite as: GLP Watchdog, Nora Bissett, "What Tripling the Dose Buys", published 2026-08-20, updated 2026-11-02. https://glpwatchdog.org/research/what-tripling-the-dose-buys

Canonical HTML page: https://glpwatchdog.org/research/what-tripling-the-dose-buys

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
